Progress on the road to better medical care for transgender patients

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 20, Issue 6, 2013, Pages 553-558

  Gardner, Ivy H ^a   Safer, Joshua D ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Female to male; Hormone therapy; Male to female; Transgender; Transsexual

Indexed keywords

CONJUGATED ESTROGEN; CYPROTERONE ACETATE; ESTRADIOL; ESTRADIOL CIPIONATE; ESTRADIOL VALERATE; ESTROGEN; ETHINYLESTRADIOL; GONADORELIN AGONIST; SPIRONOLACTONE; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE;

ANDROGEN THERAPY; ANTIANDROGEN THERAPY; BISEXUALITY; BONE DENSITY; CULTURAL COMPETENCE; DISTRESS SYNDROME; DRUG MEGADOSE; ESTRADIOL BLOOD LEVEL; FEMALE TO MALE TRANSSEXUAL; FOLLOW UP; GENDER DYSPHORIA; GENDER IDENTITY; GENERAL PRACTITIONER; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH INSURANCE; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HYPERKALEMIA; MALE TO FEMALE TRANSSEXUAL; MEDICAL CARE; MEDICAL EDUCATION; MEDICAL SPECIALIST; PATIENT CARE; PATIENT MONITORING; PERIODICITY; PUBERTY; QUALITY OF LIFE; REVIEW; SENSITIVITY TRAINING; SEX REASSIGNMENT; SEXUAL ORIENTATION; SOCIAL STIGMA; TESTOSTERONE BLOOD LEVEL; TRANSGENDERISM; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ANDROGEN ANTAGONISTS; DELIVERY OF HEALTH CARE; ESTROGENS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES FOR TRANSGENDERED PERSONS; HEALTHCARE DISPARITIES; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; QUALITATIVE RESEARCH; TESTOSTERONE; TRANSGENDERED PERSONS;

EID: 84890019886     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/01.med.0000436188.95351.4d     Document Type: Review

References (28)

1. Gates GJ. How many people are lesbian, gay, bisexual, and transgender? The Williams Institute; 2011.
2. Sanchez NF, Sanchez JP, Danoff A. Healthcare utilization, barriers to care, and hormone usage among male-to-female transgender persons in New York City. Am J Public Health 2009; 99:713-719.
3. Leinung MC, Urizar MF, Patel N, Sood SC. Endocrine treatment of transsexual persons: extensive personal experience. Endocr Pract 2013; 19:644-650. This study details demographics and trends among transgender patients seen by a single provider over two decades at a clinic in Albany, New York.
4. Gorin-Lazard A, Baumstarck K, Boyer L, et al. Is hormonal therapy associated with better quality of life in transsexuals? A cross-sectional study. J Sex Med 2012; 9:531-541. In contrast to studies that examine the effects of sex reassignment surgery on the quality of life of transgender patients, this study examines the effects of hormone therapy.
5. Obedin-Maliver J, Goldsmith ES, Stewart L, et al. Lesbian, gay, bisexual, and transgender-related content in undergraduate medical education. J Am Med Assoc 2011; 306:971-977.
6. Safer JD, Tangpricha V. Out of the shadows: it is time to mainstream treatment for transgender patients. Endocrine Pract 2008; 14:248-250.
7. Reiner WG, Gearhart JP. Discordant sexual identity in some genetic males with cloacal exstrophy assigned to female sex at birth. N Engl J Med 2004; 350:333-341.
8. Meyer-Bahlburg HFL. Gender identity outcome in female-raised 46,XY persons with penile agenesis, cloacal exstrophy of the bladder, or penile ablation. Arch Sex Behav 2005; 34:423-438.
9. Zhou J-N, Hofman MA, Gooren LJG, Swaab DF. A sex difference in the human brain and its relation to transsexuality. Nature 1995; 378:68-70.
10. Kruijver FP, Zhou JN, Pool CW, et al. Male-to-female transsexuals have female neuron numbers in a limbic nucleus. J Clin Endocrinol Metab 2000; 85:2034-2041.
11. Berglund H, Lindströ m P, Dhejne-Helmy C, Savic I. Male-to-female transsexuals show sex-atypical hypothalamus activation when smelling odorous steroids. Cerebr Cortex 2008; 18:1900-1908.
12. Rametti G, Carrillo B, Gómez-Gil E, et al. White matter microstructure in female to male transsexuals before cross-sex hormonal treatment. A diffusion tensor imaging study. J Psychiatr Res 2011; 45:199-204.
13. Rametti G, Carrillo B, Gómez-Gil E, et al. The microstructure of white matter in male to female transsexuals before cross-sex hormonal treatment. A DTI study. J Psychiatr Res 2011; 45:949-954.
14. Green R, Newman L, Stoller R. Treatment of boyhood 'transsexualism'. Arch Gen Psychiatry 1972; 26:213-217.
15. Liao L-M, Audi L, Magritte E, et al. Determinant factors of gender identity: a commentary. J Pediatr Urol 2012; 8:597-601.
16. World Professional Association for Transgender Health. Standards of care for the health of transsexual, transgender, and gender nonconforming people. 7th ed.; 2011. http://www.wpath.org/documents/Standards%20of%20Care% 20V7%20-%202011%20WPATH.pdf (Accessed on 24 December 2012)
17. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94:3132-3154.
18. Gooren LJ. Care of transsexual persons. N Engl J Med 2011; 364:2559-2560.
19. Bhasin S, Safer J, Tangpricha V. The hormone foundation 's patient guide to the endocrine treatment of transsexual persons. J Clin Endocrinol Metab 2009; 94:.
20. Bockting WO, Miner MH, Swinburne Romine RE, et al. Stigma, mental health, and resilience in an online sample of the US transgender population. Am J Public Health 2013; 103:943-951. This study characterizes how stress among transgender individuals may be minimized through access to mental health services, peer support, and social change.
21. Olshan JS, Spack NP, Eimicke T, et al. Evaluation of the efficacy of subcutaneous administration of testosterone in female to male transexuals and hypogonadal males. Endocr Rev 2013; 34:. (03-MeetingAbstracts): MON- 594.
22. Nagarajan V, Chamsi-Pasha M, Tang WHW. The role of aldosterone receptor antagonists in the management of heart failure: an update. Cleve Clin J Med 2012; 79:631-639.
23. Asscheman H, Giltay EJ, Megens JAJ, et al. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2011; 164:635-642.
24. Wierckx K, Mueller S, Weyers S, et al. Long-term evaluation of cross-sex hormone treatment in transsexual persons. J Sex Med 2012; 9:2641-2651. This study characterizes consequences of 10 years on hormone therapy for a cohort of 100 transgender patients who have undergone sex reassignment surgery.
25. Wallien MSC, Cohen-Kettenis PT. Psychosexual outcome of gender-dysphoric children. J Am Acad Child Adolesc Psychiatry 2008; 47:1413-1423.
26. Cohen-Kettenis PT, Delemarre-van de Waal HA, Gooren LJG. The treatment of adolescent transsexuals: changing insights. J Sex Med 2008; 5:1892-1897.
27. De Vries ALC, Steensma TD, Doreleijers TAH, Cohen-Kettenis PT. Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study. J Sex Med 2011; 8:2276-2283.
28. Safer JD, Pearce EN. A simple curriculum content change increased medical student comfort with transgender medicine. Endocrine Pract 2013; 33:39-44. This study demonstrates that a 1-h lecture on transgender medicine increased medical students' willingness to treat transgender patients.